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Background: Studies have shown that inflammation promoted atherosclerotic progression; however, it remains
unclear whether inflammation promoted atherosclerotic progression properties by altering cholesterol metabolism
in human macrophages. In the present study, we evaluated a potential mechanism of inflammation on atherogenic
effects. We evaluated the ability of TNFa to affect Reverse cholesterol transport (RCT) and cholesterol uptake and its
mechanism(s) of action in human macrophages.
Results: We initially determined the potential effects of TNFa on cholesterol efflux in the human macrophages.
We also determined alterations in mRNA and protein levels of ABCA1, ABCG1, LXRa, CD-36, SR-A in human
macrophages using quantitative real-time polymerase chain reaction (PCR) and Western immunoblot analyses.
The cholesterol efflux rate and protein expression of ABCA1, ABCG1, LXRa, CD-36, SR-A were quantified in human
macrophages under PKC-θ inhibition using PKC-θ siRNA. Our results showed that TNFa inhibited the rate of
cholesterol efflux and down-regulation the expression levels of ABCA1, ABCG1 and LXRa and up-regulation the
expression levels of CD-36, SR-A in human macrophages; PKC-θ inhibition by PKC-θ siRNA attenuated the effect of
TNFa on ABCA1, ABCG1, LXRa, SR-A, CD-36 expression.
Conclusions: Our results suggest TNFa alter cholesterol metabolism in human macrophages through the inhibition
of Reverse cholesterol transport and enhancing cholesterol uptake via PKC-θ-dependent pathway, implicating a
potential mechanism of inflammation on atherogenic effects.
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Atherosclerosis is a chronic inflammatory disease charac-
terized by early and prolonged presence of macrophages
within the innermost layer of the arterial wall [1]. Arterial-
wall macrophages uncontrolled uptake of modified low-
density lipoprotein (LDL) and caused foam-cell formation,
resulting in the development of atherosclerosis [2]. Three
main mechanisms are known to be anti-atherosclerotic:
Endothelial progenitor cells, plaque neovascularization
and reverse cholesterol transport (RCT). Recently, RCT
has received special attention in the literature. The entire
macrophage-specific RCT, regulated predominantly by the
macrophage transporters ABCA1, ABCG1 [3], is a process
to remove excess cholesterol from peripheral macrophages* Correspondence: zysong2010@126.com
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reproduction in any medium, provided the orto HDL and transport them to the liver for subsequent
elimination as bile acids and neutral steroids [4].
Tumour necrosis factor alpha (TNFa) is a pro-
inflammatory cytokine involved in initiating inflammatory
responses [5]. Human studies and animal models impli-
cate TNFa in atherosclerotic plaque formation [6]. TNFa
is produced primarily by macrophages, but also by a broad
variety of cell types including lymphoid cells, mast cells,
endothelial cells; it promotes macrophage activation,
lymphocyte trafficking and homeostasis,cellular infiltration
of the plaque and stimulates production of other cytokines
which increase plaque instability leading to thrombus
formation [7]. Cross-sectional data indicate positive as-
sociations between TNFa and degree of atherosclerosis
or level of prevalent CVD [8]. However, it is still unclear
that TNFa promote atherosclerotic plaque formation
whether related to alter cholesterol metabolism in hu-
man macrophages. Therefore, we set out to investigate
the effect of TNFa treatment on Reverse cholesterolLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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TNFa (Hoffmann-La Roche Ltd, Basel, Switzerland),
Total RNA extraction reagent RNAiso Plus, PrimeScript
RT reagent kit, SYBR-Green PCR kit (Takara, Japan).
Western immunoblot reagents were purchased from the
Beyotime Institute of Biotechnology (China). All other
chemicals were of the best grade available from commer-
cial sources.
Cell culture
Human peripheral blood monocytes were isolated from
three healthy volunteers (Lin Wang, Peng Zhou, Rui
Ma, Department of Cardiology, Southwest Hospital,
The Third Military Medical University, Chongqing,
China) using Ficoll/Hypaque gradient centrifugation.
The pooled monocytes from the volunteers were incu-
bated in DMEM supplemented with 10% autologous
serum for 10 days so that they would differentiate into
macrophages. This research carried out on humans was
in compliance with the Helsinki Declaration.
Cellular cholesterol efflux experiments
Human macrophages were cultured as indicated above.
Human macrophages were then labeled with 3H-cholesterol
(0.3 μCi/mL) in serum-free DMEM medium containing
50 μg/ml ox-LDL and 0.2% bovine serum albumin (BSA)
for 24 h. The cells were washed twice with phosphate
buffered saline (PBS) and incubated in 2 mL of DMEM
media containing 0.2% BSA without or with TNFa at 5 ng/
ml, 10 ng/ml for 48 h. The media were then replaced with
DMEM containing 0.2% BSA in the presence of lipid-free
apoA-I (10 μg/mL) or HDL (50 μg/mL) for 24 h. Efflux
media was obtained at the times designated and
centrifuged to remove floating cells. Monolayers were
washed in PBS in duplicate, and cellular lipids were
extracted using isopropanol. Media and cell-associated
[3H] cholesterol were then measured using liquid scintilla-
tion counting. Percent efflux was calculated with the
following equation: [total media counts/(total cellular
counts + total media counts)] × 100%.
RNA isolation and real-time quantitative polymerase
chain reaction analyses
Total RNA was extracted using RNAiso Plus reagent in
accordance with manufacturer’s instructions. The PCR
primers were synthesized by Shanghai Sangon (Shanghai,
China), and the primer sequences used were the follow-
ing: ABCA1: forward primer: 5′-AAG CCA AGC ATC
TTC AG TTC-3′, reverse primer: 5′-CCA TAC AGC
AAG AGC AGA AGG-3′; ABCG1: forward primer: 5′-ATA CAG GGG AAA GGT CTC CAA T-3′, reverse pri-
mer: 5′-CCC CCG AGG TCT CTC TTA TAG T-3′;
LXRa: forward primer: 5′-AGG CCG GTG CTG AGT
ATG TC-3′, reverse primer: 5′-GGG CTC CAT AAA
GTC ACC AA-3′; CD36: forward primer: 5′-GTC TTC
CCA ATA AGC ATG TCT CC-3′, reverse primer: 5′-
GTC TTC CCA ATA AGC ATG TCT CC-3′; SR-A:
forward primer: 5′-TGA ACG AGA GGA TGC TGA
CTG −3′, reverse primer: 5′-TGT CAT TGA ACG TGC
GTC AAA-3′; PKC-θ: forward primer: 5′-ACA TCT
ACA GTA TAC TCA CAG-3′; reverse primer: 5′-ACT
CGT ACT ATG GAC CAC ATC-3′; GAPDH: forward
primer: 5′- AGG CCG GTG CTG AGT ATG TC −3′,
reverse primer: 5′- TGC CTG CTT CAC CAC CTT CT −
3′. Real-time quantitative polymerase chain reaction (PCR)
was performed with SYBR® Premix Ex Taq™ II, on a Bio-
Rad LightCycler with an iQ3.1 realtime PCR system. Melt
curve analyses of all real-time PCR products was used to
produce a single DNA duplex. Quantitative measurements
were obtained using the ΔΔ Ct method, and expression of
GAPDH was used as an internal control.
Western immunoblot analyses
Cells were harvested and protein extracts prepared in ac-
cordance with the manufacturer’s instructions. Western
immunoblot analyses [12% SDS-PAGE; 30 μg protein per
lane] were then performed using rabbit anti-ABCA1, anti-
ABCG1, anti-LXRα, anti-CD-36, anti-SR-A and anti-
GAPDH (Abcam, USA)-specific antibodies. Proteins were
visualized using enhanced chemiluminescence.
Transfections for LXRa silencing and screening effective
PKC-θ siRNA fragments
The PKC-θ-siRNA specific for mouse PKC-θ and non-
silencing (control) siRNAs were synthesized by Shanghai
Genechem (Shanghai, China). Human macrophages (1 ×
106cells/well) were transfected using Lipofectamine 2000
(Invitrogen). Following 48 h transfection,the second
siRNA fragment of PKC-θ suppressed expression of the
PKC-θ gene by 75% according to RT-PCR analyses. The
oligonucleotide sequences used to construct siRNA used
in this study were: 5-ATC TCA ATG ACG CTG AGT
T-3 for PKC-θ (PKC-θ-siRNA).
LXRa siRNA transfection and western immunoblot
analyses
Human macrophages were grown in culture flasks at a
density of 1 × 107/ml for 12 hours, washed with PBS,
and TNFa at 10 ng/ml, 10 ng/ml was added to the
DMEM culture media containing 10% human serum.
The negative control was added to the first culture flask
and PKC-θ-siRNA was added to the remaining flasks
and cultured for 96 hours. Cells were harvested and pro-
tein extracts were prepared in accordance with the
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jected to Western immunoblot analyses [12% SDS-PAGE;
60 μg protein per lane] using rabbit anti-ABCA1, anti-
ABCG1, anti-LXRα, anti-CD36, anti-SR-A and anti-
GAPDH (Abcam, USA)-specific antibodies. Proteins were
visualized using enhanced chemiluminescence methods.
Statistical analyses
Data are expressed as mean ± standard error of the mean
(SEM). Results were analyzed using ANOVA with SPSS
13.0 software. P < 0.05 was considered statistically signifi-
cant. All experiments were performed in at least triplicate.
Results
TNFa inhibited cholesterol efflux in human macrophages
We initially examined the effect of TNFa on cholesterol
efflux in human macrophages using liquid scintillation
counting assays. Figure 1(A, B) shows that TNFa at
5 ng/ml, 10 ng/ml obvious inhibited apoA-I- and HDL-
mediated cholesterol efflux in human macrophages com-
pared with the negative control.
TNFa down-regulated the mRNA and protein expression
of ABCA1, ABCG1, LXRa in human macrophages
To further explore the effects of TNFa on human
marcophage-mediated RCT, we examined the effects of
TNFa on ABCA1, ABCG1 and LXRa expression in hu-
man macrophages using real-time quantitative PCR and
Western immunoblot analyses. Our results showed that
TNFa at 5 ng/ml, 10 ng/ml significantly decreased the
mRNA (Figure 2) and protein (Figure 3A, B) expression






















































Figure 1 TNFa inhibit cholesterol efflux from human
macrophages. After human macrophages were labeled with 3H-
cholesterol, the indicated doses of either TNFa or the vehicle were
added to the cultures, which were then incubated in the presence
of either 10 μg/mL human apoA-I (A) or 50 μg/mL of human HDL
(B) for 24 h. Cholesterol efflux was determined as described in
Methods. Data are presented as mean ± SEM, *P < 0.05 vs control.TNFa up-regulated the mRNA and protein expression of
CD-36, SR-a in human macrophages
We then examined the effects of TNFa on the expression
levels of CD-36, SR-A expression in human macrophages.
As demonstrated in Figure 2 that the mRNA expression
levels of CD-36, SR-A were significantly up-regulated in
human macrophages treated with TNFa at 5 ng/ml, 10 ng/
ml compared with the negative control. The protein ex-
pression of CD-36, SR-A were also significantly up-
regulated (Figure 3A, C) in human macrophages treated
with TNFa at 5 ng/ml, 10 ng/ml compared with the nega-
tive control.PKC-θ inhibition by siRNA significantly attenuated the
effect of TNFa on ABCA1, ABCG1, LXRa, CD-36, SR-a
expression
We next investigated the effect of treatment with PKC-θ
siRNA on TNFa (10 ng/ml)-induced expression of
ABCA1, ABCG1, LXRa, CD-36, SR-A. PKC-θ siRNA
suppressed the expression of PKC-θ gene (Figure 4D)
by 76% according to Western immunoblot analyses. As
showed in Figure 4(A, B, C ) that PKC-θ siRNA signifi-
cantly attenuated the effect of TNFa on ABCA1,
ABCG1, LXRa, CD-36, SR-A expression.Discussion
TNFa plays a central role in inflammation; it induces
the expression of other proinflammatory molecules,
chemotactic cytokines and adhesion factors [9]. In vivo
and in vitro studies have shown that high levels of TNFa
lead to exacerbation of the inflammatory response [10].
This, together with its potent immunomodulator activ-
ities, has been suggested as important to the pathogen-
esis of diseases such as asthma and Atherosclerosis [11].
In this study, we evaluated a potential mechanism of
TNFa on atherogenic effects. As shown in Figure 1A
and B, TNFa at 5 ng/ml, 10 ng/ml significantly inhibited
both apoA-I- and HDL-mediated cholesterol efflux
from human macrophages. Next, we determined the
mRNA and protein levels of ABCA1, ABCG1, LXRa in
order to elucidate the molecular mechanisms under-
lying the inhibited cholesterol efflux in human macro-
phages due to TNFa.
A previous study noted that ATP binding cassette
transporters (ABCA1, ABCG1) and LXRa are the best
characterized cellular transporters/receptor involved
in macrophage RCT [12]. The initial comparison of
macrophage-specific RCT between ABCA1-deficient
and wild-type mice showed direct evidence that ABCA1
deficiency reduces RCT from macrophages to feces
in vivo [13]. ABCG1 is another ABC transporter that is
able to load more cholesterol onto mature HDLs from
the peripheral tissues and is important in allowing









































































































































Figure 2 Human macrophages were treated either with or without TNFa at 5 ng/ml, 10 ng/ml for 24 h. (A) ABCA1, (B) ABCG1, (C) LXRa,
(D) CD-36, (E) SR-A gene expression were measured using real-time quantitative PCR. Similar results were obtained in three independent
experiments. Data are mean ± SEM. *P < 0.05 vs control.
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ally preventing atherosclerotic vascular disease [14].
Our results showed that TNFa at 5 ng/ml, 10 ng/ml
significantly decreased the mRNA expression levels of
ABCA1, ABCG1 and LXRa compared with the control
group (Figure 2), resulting in significantly down-
regulated protein expression levels in human macro-
phages (Figure 3A, B). This indicates that TNFa inhibit
reverse cholesterol transport in human macrophages
via ABCA1 and ABCG1 -mediated pathways.
Interestingly, we also found that the mRNA (Figure 2)
and protein (Figure 3A, C) expression levels of pattern-
recognition scavenger receptors CD-36 and SR-A, were
significantly up-regulated in human macrophages treated
with TNFa at 5 ng/ml, 10 ng/ml. SR-A belongs to scav-
enger receptor A family, and has been implicated in ath-
erosclerosis [15]. CD36 is a member of the class B
scavenger receptor family and its activation has been im-
plicated in foam cell formation. It appears that SR-A and
CD36 account for greater than 90% of the lipid accumu-
lation in macrophages exposed to oxidized LDL [16]. So
it suggested that TNFa can promote cholesterol uptakeby enhancing the expression of CD-36 and SR-A in hu-
man macrophages.
Protein kinase C (PKC) comprises a family of serine/
threonine kinases that are involved in the regulation of
many cellular responses, including proliferation, differ-
entiation, stress responses, and lipid metabolism [17].
PKC isozymes have been classified in three subfamilies:
conventional (cPKCs α, βI, βII and γ), novel (nPKCs δ,
ε, θ and η) and atypical (aPKCs λ, ι, μ, ζ). Conventional
PKCs are regulated by diacylglycerol (DAG), hos-
phatidylserine and calcium, whereas novel PKCs are
calcium-independent, but regulated by DAG and phos-
phatidylserine, and atypical PKC isoforms are regulated
by phosphatidylserine, but calcium, DAG- and TPA-
independent [18]. Previous study showed that PKC acti-
vation mediates production of granulocyte/macrophage
colony-stimulating factor (GM-CSF), which plays a
priming role in Ox-LDL-induced macrophage prolifera-
tion [19]. Protein kinase C-β and –δ mediate cholesterol
accumulation in PMA-activated macrophages and another
report shows that stably overexpressed a dominant-
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Figure 3 Human macrophages were treated without or with TNFa at at 5 ng/ml, 10 ng/ml for 48 h. (A) The Relative protein fold change
of ABCA1; (B) The Relative protein fold change of ABCG1; (C) The Relative protein fold change of LXRa; (D) The Relative protein fold change of
CD-36; (E) The Relative protein fold change of SR-A. (F) ABCA1, ABCG1, LXRa and (G) CD-36, SR-A protein expression were measured using
Western immunoblotting techniques. Similar results were obtained in three independent experiments. Data are mean ± SEM. *P < 0.05 vs control.
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tein induces TNF-α and IL-10 production via a
PKC-βII and -δ isozymes dependent way in human
macrophages [22]. 6-Gingerol inhibits ROS and iNOS
in lipopolysaccharide-stimulated mouse macrophages,
through the suppression of PKC-α and NF-κB path-
ways, [23].
PKC-θ mediates the critical T cell receptor (TCR) sig-
nals selectively required for T cell activation in vivo [24].
PKC-θ plays a crucial role in the activation of various
transcription factors such as NF-kB, AP-1 and nuclear
factor of activated T cells (NFAT) [25,26]. Mature PKC-θ−/−T cells failed to proliferate and produce interleukin 2
(IL-2) upon TCR stimulation due to defective activation
of NF-kB and AP1 [27]. Mice deficient in other isoforms
of PKC do not have a defect in T cell activation, thereby
reinforcing the importance of PKC-θ in T cell activation
[28]. Considering the multiple functions of PKC-θ in T
cell activation, it would be interesting to examine
whether PKC-θ plays a role in the effect of TNFa on
ABCA1, ABCG1, LXRa, SR-A, CD-36 expression in hu-
man macrophages.
To confirm whether PKC-θ is involved in the TNFa-
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Figure 4 Human macrophages were transfected with either the negative control or PKC-θ-siRNA and then incubated without or with
TNFa at 10 ng/ml, 10 ng/ml for 96 h. The Relative protein fold change of (A) ABCA1, (B) ABCG1, (C) LXRa (D) CD-36, (E) SR-A were shown in
Figure 4. (G) ABCA1, ABCG1, LXRa and (H) CD-36, SR-A protein expression were measured using Western immunoblotting techniques. Human
macrophages were transfected with either the negative control or PKC-θ-siRNA and then incubated for 96 h. (F) Relative protein fold change of
PKC-θ in human macrophages transfected with either the negative control or PKC-θ-siRNA. (I) PKC-θ protein expression were measured using
Western immunoblotting techniques. Similar results were obtained in three independent experiments. Data are presented as mean ± SEM,
*P < 0.05 vs control.
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SR-A in human macrophages, we utilized PKC-θ-siRNA
to inhibit PKC-θ. The results show that PKC-θ-siRNA sig-
nificantly attenuated the effect of TNFa on ABCA1,
ABCG1, LXRa, SR-A, CD-36 expression compared with
the negative control (Figure 4A, B, C). This phenomenon
confirmed that PKC-θ is involved in the effect of TNFa on
ABCA1, ABCG1, LXRa, SR-A, CD-36 expression in hu-
man macrophages. These data suggest that PKC-θ activity
is involved in the effect of TNFa on ABCA1, ABCG1,LXRa, SR-A, CD-36 expression in human macrophages,
and the isotype-selective inhibitor to PKC-θ may suppress
atherosclerotic progression.
Conclusion
These results suggest that TNFa promote atherosclerotic
progression by altering cholesterol metabolism though
inhibiting Reverse cholesterol transport and enhancing
cholesterol uptake in human macrophages via PKC-θ-
dependent pathway.
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